Supplemental Information for "Optimal Donor Selection Across Multiple Outcomes For Hematopoietic Stem Cell Transplantation By Bayesian Nonparametric Machine Learning"

1 Introduction

For this study, we rely upon Nonparametric Failure Time Bayesian Additive Regression Trees (NFT BART) methodology (Sparapani et al., 2023). NFT BART is a nonparametric ensemble of trees survival analysis approach that does not rely on precarious restrictive assumptions such as proportionality, linearity nor homoskedasticity. These features are particularly pertinent for our study examining predictors for mortality risk in patients undergoing hematopoietic stem cell transplant (HSCT) for blood-borne cancer, where heteroskedasticity and non-proportional hazards are likely to be present.

Here, we give a general summary of NFT BART and its most relevant aspects for this study. For more details on NFT BART, see Sparapani et al. (2023) and the corresponding Web Supplement. In Section 2, we review the BART and Heteroskedastic BART (HBART) priors. Section 3 introduces the NFT BART model. Section 4 provides the default settings for the Low Information Omnibus Dirichlet Process Mixtures (LIO DPM) hierarchical prior. In Section 5, we provide DPM density, distribution, hazard and survival function estimates for NFT BART. In Section 6, we show how the restricted mean survival time (RMST) can be calculated for an NFT BART model. In Section 7, we demonstrate how to summarize an NFT BART model with marginal effects by Friedman's partial dependence (FPD) function. In Section 8, we provide a brief description of the **nftbart** R package. You will find additional details about model variables in Section 9.1 and their relationship of with OS/EFS in Section 9.2.

2 BART and Heteroskedastic BART

2.1 The BART prior

BART (Chipman et al., 2010) is a sum of binary trees nonparametric machine learning regression model where the relationship between the outcome, y_i , and the covariates, x_i , is

learned from the data itself. We restrict our attention to a continuous outcomes for now. Let y_i be a continuous outcome with i = 1, ..., N indexing subjects and x_i is a vector of covariates. The BART model has the following form:

$$y_{i} = \mu(\boldsymbol{x}_{i}) + \epsilon_{i} \qquad \mu \stackrel{\text{prior}}{\sim} \text{BART}(a, b, H, \kappa, \widetilde{\mu}) \qquad \mu(\boldsymbol{x}_{i}) \equiv \widetilde{\mu} + \sum_{h=1}^{H} g(\boldsymbol{x}_{i}; \mathcal{T}_{h}, \mathcal{L}_{h})$$

$$\epsilon_{i} | \sigma^{2} \stackrel{\text{iid}}{\sim} \text{N}(0, w_{i}^{2} \sigma^{2}) \qquad \sigma^{2} \stackrel{\text{prior}}{\sim} \lambda \nu \chi^{-2}(\nu)$$

$$(1)$$

where $\tilde{\mu}$ is a constant that centers the data (a default choice is $\tilde{\mu} = \overline{y}$). The binary tree regression function is $g(\boldsymbol{x}; \mathcal{T}, \mathcal{L})$ with \mathcal{T} denoting the nodes of the tree (as well as whether they are branch decision rules or leaves) and \mathcal{L} denoting its leaf values. The variance multiples, w_i^2 , are known constants dictated by the problem of interest; when unneeded, simply let $w_i \equiv 1$. Prior argument default settings are employed that often provide adequate fits. For example, the number of trees, H, is *large* with typical settings of 50, 100 or 200 where 50 is a default with reasonable performance (Bleich et al., 2014).

2.2 The Heteroskedastic BART (HBART) prior

Heteroskedastic BART (Pratola et al., 2020) is an extension to BART where we fit both a mean function, μ , and a variance function, σ^2 , for a flexible nonparametric function of \boldsymbol{x} . This model can be written as follows:

$$y_{i} = \mu(\boldsymbol{x}_{i}) + \epsilon_{i} \qquad \mu \stackrel{\text{prior}}{\sim} \text{BART}(a, b, H, \kappa, \widetilde{\mu}) \qquad \mu(\boldsymbol{x}_{i}) \equiv \widetilde{\mu} + \sum_{h=1}^{H} g(\boldsymbol{x}_{i}; \mathcal{T}_{h}, \mathcal{L}_{h})$$

$$\epsilon_{i} | \sigma^{2} \stackrel{\text{ind}}{\sim} \text{N}(0, \ w_{i}^{2} \sigma^{2}(\boldsymbol{x}_{i})) \quad \sigma^{2} \stackrel{\text{prior}}{\sim} \text{HBART}(\widetilde{a}, \widetilde{b}, \widetilde{H}, \widetilde{\lambda}, \widetilde{\nu}) \quad \sigma^{2}(\boldsymbol{x}_{i}) \equiv \prod_{h=1}^{\widetilde{H}} g(\boldsymbol{x}_{i}; \widetilde{\mathcal{T}}_{h}, \widetilde{\mathcal{L}}_{h}) \qquad (2)$$

where the covariates of $\mu(.)$ and $\sigma^2(.)$ do not need to be the same, but we denote them by \boldsymbol{x}_i merely for notational convenience throughout. Recommended prior default argument settings often provide adequate fitting: $\kappa = 5$ and $\widetilde{\mu} = \overline{y}$ for μ ; $\widetilde{\lambda} = s_y^2$ and $\widetilde{\nu} = 10$ for σ^2 ; with $a = \widetilde{a} = 0.95$ and $b = \widetilde{b} = 2$ for both.

2.3 Binary tree regression models

Here we present a brief overview of binary tree regression models as well as delving into the details for the BART and HBART priors. $[\theta]$ is the generic bracket notation of Gelfand and Smith (1990) denoting the distribution of θ , e.g., the prior for θ is $[\theta]$, the likelihood $[y|\theta]$ and the posterior $[\theta|y]$. For the BART prior, it is assumed that the trees are independent and the leaves are conditionally independent given the trees as $[\mathcal{T}, \mathcal{L}] \stackrel{\text{prior}}{\propto} \prod_h [\mathcal{T}_h] [\mathcal{L}_h | \mathcal{T}_h]$ where \mathcal{T}_h represents a tree and \mathcal{L}_h the leaves of that tree (the HBART prior is analogous: $[\widetilde{\mathcal{T}}, \widetilde{\mathcal{L}}]$).

2.4 The variance prior for BART

The prior variance is independent of the trees and leaves. It is weakly informed by the data via the construction of $\hat{\sigma}^2$ that defaults to either the variance of y itself or the variance of the random error from a linear regression. A default value of $\nu = 3$ is assumed and λ is chosen given the distribution, $\sigma^2 \stackrel{\text{prior}}{\sim} \lambda \nu \chi^{-2}(\nu)$, such that $P[\sigma^2 < \hat{\sigma}^2] = q$ where the default for q = 0.9. For more details of the variance prior see Chipman et al. (2010).

2.5 The tree prior for BART and HBART

To develop the tree prior, we need to introduce some notation: $[\mathcal{T}_h] = [\beta_{h1}, \dots, \beta_{hC_h}]$ where $n = 1, \dots, C_h$ is the index for nodes. For each node, the depth of the tree can be deduced from the node index itself: $d(n) = \lfloor \log_2 n \rfloor$. Furthermore, at tier d(n) = d, the potential nodes are numbered as $n = 2^d, \dots, 2^{d+1} - 1$ from left to right where a parent's children are 2n and 2n + 1 at depth d + 1 (but of course they need not all exist except n = 1). Rather than a tier's height, it is tier depth to be considered since binary trees are typically drawn growing downward (as opposed to upward like wooden trees); see the schematic diagram: Supplement Table 1.

Tier				Node			
0				1			
1		2				3	
2	4		5		6		7
:							
d		2^d			2^d	+1_	1

Supplement Table 1: Schematic diagram of a binary tree.

Trees with many branches will likely over-fit to the training data at the expense of predictive performance on unseen validation data without a regularization penalty. Therefore, the BART and HBART priors have a branching penalty where the regularity increases with the depth. If we assume a success is a branch decision rule and a failure is a terminal leaf value, then we have independent Bernoulli random variables $\beta_{hn} \stackrel{\text{prior}}{\sim} B(p(d(n)))$ where $p(d) = a(1+d)^{-b}$ and q(d) = 1-p(d). The prior argument defaults are a = 0.95 and b = 2 (for a discussion of this penalty, see Chipman et al. (1998, 2010); Ročková and Saha (2019)). So the expected number of branches (leaves), in prior probability, is 1 (2) with probability $P[\beta_{h1} = 1, \beta_{h2} = \beta_{h3} = 0] = p(0)q(1)^2 \approx 0.55$ and 2 (3) with probability $2P[\beta_{h1} = \beta_{h2} = 1, \beta_{h3} = \beta_{h4} = \beta_{h5} = 0] = 2p(0)p(1)q(1)q(2)^2 \approx 0.27$ (doubled due to symmetry), i.e., trees with only 1 or 2 branches (2 or 3 leaves) would predominate in prior probability of roughly 0.82.

2.6 The leaf prior

2.6.1 BART

A priori, each of the leaf values are independent: $[\mathcal{L}_h|\mathcal{T}_h] = \prod_{l_h} [\mu_{hl_h}|\mathcal{T}_h]$ where $\mathcal{L}_h = [\mu_{hl_h}]$ is a vector of leaf values for tree h and $l_h \in \{n : \beta_{hn} = 0\}$ is the index for the leaves. Suppose that $y \in [y_{\min}, y_{\max}]$ and denote $\widetilde{\mu}_h$ as the leaf output values from each tree corresponding to the vector of covariates, \boldsymbol{x} . If $\widetilde{\mu}_h|\mathcal{T}_h \stackrel{\text{iid}}{\sim} \mathrm{N}(0, \sigma_\mu^2)$, then the model estimate is $\widehat{y} = \mathrm{E}[y] = \widetilde{\mu} + \sum_h \widetilde{\mu}_h$ where $\widehat{y} \sim \mathrm{N}(\widetilde{\mu}, H\sigma_\mu^2)$. We choose a value for σ_μ which is the solution to the equations $y_{\min} = \widetilde{\mu} - \kappa \sqrt{H}\sigma_\mu$ and $y_{\max} = \widetilde{\mu} + \kappa \sqrt{H}\sigma_\mu$, i.e., $\sigma_\mu = \frac{y_{\max} - y_{\min}}{2\kappa \sqrt{H}}$. Therefore, we arrive at $\mu_{hl_h}|\mathcal{T}_h \stackrel{\text{prior}}{\sim} \mathrm{N}\left(0, \frac{\tau^2}{4\kappa^2 H}\right)$ where $\tau = y_{\max} - y_{\min}$. So, the default value, $\kappa = 2$, corresponds to \widehat{y} falling within the extrema with approximately 0.95 probability. The values y_{\min} and y_{\max} can be elicited from expert opinion as the 2.5 and 97.5 percentiles respectively to set τ . By default, τ is set to the extrema from the observed data.

2.6.2 HBART

The BART leaf prior is as above except that the default is now $\kappa = 5$. Here, we discuss the prior for $\widetilde{\mathcal{L}}_h|\widetilde{\mathcal{T}}_h$. For a more detailed discussion of the HBART prior specification, please see Pratola et al. (2020). A priori, each of the leaf values are independent: $\left[\widetilde{\mathcal{L}}_h|\widetilde{\mathcal{T}}_h\right] = \prod_{l_h} \left[\sigma_{hl_h}^2|\widetilde{\mathcal{T}}_h\right]$ where $\widetilde{\mathcal{L}}_h = \left[\sigma_{hl_h}^2\right]$ is a vector of leaf values for tree h and $l_h \in \{n: \widetilde{\beta}_{hn} = 0\}$ is the index for the leaves. The prior for the leaves is $\sigma_{hl_h}^2 \stackrel{\text{prior}}{\sim} \lambda \nu \chi^{-2}(\nu)$ so we need to determine the defaults for λ and ν . Suppose that we consider a homoskedastic BART model: $\mathrm{E}\left[\sigma^2\right] = \frac{\widetilde{\lambda}\widetilde{\nu}}{\widetilde{\nu}-2}$ with defaults $\widetilde{\lambda} = \widehat{\sigma}^2$ and $\widetilde{\nu} = 10$. Compare that with the corresponding HBART setting: $\mathrm{E}\left[\sigma^2(\boldsymbol{x})\right] = \prod_h \mathrm{E}\left[\widetilde{\sigma}_h^2\right] = \lambda^{\widetilde{H}}\left[\frac{\nu}{\nu-2}\right]^{\widetilde{H}}$ (where $\widetilde{\sigma}_h^2$ represents the leaf from tree h corresponding to \boldsymbol{x}). Since $\frac{\widetilde{\lambda}\widetilde{\nu}}{\widetilde{\nu}-2} \equiv \lambda^{\widetilde{H}}\left[\frac{\nu}{\nu-2}\right]^{\widetilde{H}}$, we use the values $\lambda = \widetilde{\lambda}^{1/\widetilde{H}}$ and $\nu = 2\left[1-\left(1-\frac{2}{\widetilde{\nu}}\right)^{1/\widetilde{H}}\right]^{-1}$.

3 NFT BART

NFT BART is a largely assumption free survival analysis model having a nonparametric distribution for the random error while allowing the covariates to explain both a location shift and a scale change. Here we present a brief introduction; for more details see Sparapani et al. (2023). For notational convenience, we move fluidly between a parameterization based on the precision, τ_i , to the variance, $\sigma_i^2 = \tau_i^{-1}$, since it is generally arbitrary. The NFT BART model is as follows (let the unknown parameters be denoted $\boldsymbol{\theta}$):

$$\begin{cases}
y_i = \mu(\boldsymbol{x}_i) + \epsilon_i & \mu \stackrel{\text{prior}}{\sim} BART(a, b, H, \kappa, \widetilde{\mu}) \\
\epsilon_i | \boldsymbol{\theta} \stackrel{\text{ind}}{\sim} N(\mu_i, \ \sigma_i^2 \sigma^2(\boldsymbol{x}_i)) & \sigma^2 \stackrel{\text{prior}}{\sim} HBART(\widetilde{a}, \widetilde{b}, \widetilde{H}, \widetilde{\lambda}, \widetilde{\nu})
\end{cases}$$
(3)

subject to the constraints $N^{-1}\sum_{i}\mu_{i}=0$ and $N^{-1}\sum_{i}\sigma_{i}^{2}=1$ for identifiability (we defer the description of priors for μ_{i} and τ_{i} until the next Section 4). Right-censoring is handled by data augmentation as follows:

$$y_i \begin{cases} \sim N(\mu_i + \mu(\boldsymbol{x}_i), \ \sigma_i^2 \sigma^2(\boldsymbol{x}_i)) \ I(\log t_i, \infty) & \text{if } \delta_i = 0, \text{ right-censoring} \\ = \log t_i & \text{if } \delta_i = 1, \text{ an event time} \end{cases}$$
(4)

and, conveniently, left-censoring can be handled similarly, but that is not shown for simplicity. As noted, both μ_i and σ_i are constrained. Posterior inference can reliably be performed in the unconstrained setting; however, convergence diagnostics are more challenging without constraints. Furthermore, in the unconstrained setting, our experience has been that MCMC mixing is inefficient making convergence diagnostics even more important at the same time that they are more difficult to ascertain. Therefore, we recommend constrained DPM for NFT BART (Yang et al., 2010).

4 The LIO DPM prior hierarchy

Like BART and HBART, the LIO DPM prior hierarchy has robust default arguments that should be sufficient in most circumstances. Due to the identifiability constraints on (μ_i, τ_i) , the defaults fall into what is known as the standardized setting (Shi et al., 2019). The DPM LIO prior hierarchy employed by NFT BART is as follows:

$$G|\alpha \overset{\text{prior}}{\sim} \text{DP}\left(\alpha, \ F_{(\mu_0, \tau_0 | k_0, b_0)}\right) \quad (\mu_i, \tau_i)|G \overset{\text{prior}}{\sim} G$$

$$\alpha \overset{\text{prior}}{\sim} \text{Gamma} (1, \ 0.1) \qquad \qquad \tau_0 |b_0 \overset{\text{prior}}{\sim} \text{Gamma} (1.5, \ b_0) \quad b_0 \overset{\text{prior}}{\sim} \text{Gamma} (2, \ 1)$$

$$\mu_0 | (\tau_0, k_0) \overset{\text{prior}}{\sim} \text{N}\left(0, \ \tau_0^{-1} k_0^{-1}\right) \qquad k_0 \overset{\text{prior}}{\sim} \text{Gamma} (3, \ 7.5)$$

where the joint base distribution $[\mu_0, \tau_0 | k_0, b_0]$ is drawn by the conditionals $[\tau_0 | b_0] [\mu_0 | \tau_0, k_0]$.

5 Posterior inference for NFT BART

Notationally, let $\boldsymbol{\theta} = (\mu, \sigma^2, \boldsymbol{\mu}, \boldsymbol{\tau}, \alpha)$ represent the unknown parameters where $\boldsymbol{\theta}_m$ is the mth posterior draw. Our primary interest with respect to statistical inference here is the impact of the covariates on the time to an event. In particular, the survival function, $S(t|\boldsymbol{x}) = 1 - F(t|\boldsymbol{x})$, plays a central role along with the hazard function, $h(t|\boldsymbol{x}) = f(t|\boldsymbol{x})/S(t|\boldsymbol{x})$. The nonparametric estimation of survival and hazard is arrived at by aggregating over the DPM clusters (Escobar and West, 1995) to create estimates of the distribution, $F(t|\boldsymbol{x})$, and density, $f(t|\boldsymbol{x})$. For NFT BART, we arrive at the following (conditioning on $\boldsymbol{\theta}_m$ suppressed

for notational convenience):

$$F_{m}(t|\mathbf{x}) = \int \Phi \left\{ \frac{\log t - \mu_{*} - \mu_{m}(\mathbf{x})}{\sigma_{*}\sigma_{m}(\mathbf{x})} \right\} G_{m}(\mathrm{d}\mu_{*}, \mathrm{d}\sigma_{*})$$

$$= \sum_{j=1}^{\infty} \omega_{j} \Phi \left\{ \frac{\log t - \mu_{j}^{*} - \mu_{m}(\mathbf{x})}{\sigma_{j}^{*}\sigma_{m}(\mathbf{x})} \right\}$$

$$\approx \sum_{j=1}^{K_{m}} \omega_{jm} \Phi \left\{ \frac{\log t - \mu_{jm}^{*} - \mu_{m}(\mathbf{x})}{\sigma_{jm}^{*}\sigma_{m}(\mathbf{x})} \right\}$$

$$f_{m}(t|\mathbf{x}) = \int \frac{\Phi \left\{ \frac{\log t - \mu_{*} - \mu_{m}(\mathbf{x})}{\sigma_{*}\sigma_{m}(\mathbf{x})} \right\}}{t\sigma_{*}\sigma_{m}(\mathbf{x})} G_{m}(\mathrm{d}\mu_{*}, \mathrm{d}\sigma_{*})$$

$$= \sum_{j=1}^{\infty} \frac{\omega_{j} \Phi \left\{ \frac{\log t - \mu_{j}^{*} - \mu_{m}(\mathbf{x})}{\sigma_{j}^{*}\sigma_{m}(\mathbf{x})} \right\}}{t\sigma_{j}^{*}\sigma_{m}(\mathbf{x})}$$

$$\approx \sum_{j=1}^{K_{m}} \frac{\omega_{jm} \Phi \left\{ \frac{\log t - \mu_{jm}^{*} - \mu_{m}(\mathbf{x})}{\sigma_{jm}^{*}\sigma_{m}(\mathbf{x})} \right\}}{t\sigma_{jm}^{*}\sigma_{m}(\mathbf{x})}$$

$$\approx \sum_{j=1}^{K_{m}} \frac{\omega_{jm} \Phi \left\{ \frac{\log t - \mu_{jm}^{*} - \mu_{m}(\mathbf{x})}{\sigma_{jm}^{*}\sigma_{m}(\mathbf{x})} \right\}}{t\sigma_{jm}^{*}\sigma_{m}(\mathbf{x})}$$

where $\Phi(.)$ and $\phi(.)$ are the standard Normal distribution and density functions, respectively, while m = 1, ..., M indexes draws from the posterior. In equations (6) and (7), we adopt the notation (μ_*, σ_*) for constrained posterior predictive draws from G_m and (μ_j^*, σ_j^*) for those values that are shared by the jth atomic cluster. But, drawing from a constrained G_m requires unconstrained draws needing centering/scaling. Therefore, we propose a reasonable compromise for computational convenience by substituting constrained $(\mu_{jm}^*, \sigma_{jm}^*)$ draws from the posterior for (μ_j^*, σ_j^*) that provides fairly effective estimation performance.

Now we can calculate our survival function estimate by the mean with respect to the posterior as $\hat{S}(t|\mathbf{x}) = M^{-1} \sum_{m} S_m(t|\mathbf{x})$ (and the hazard function is estimated similarly). Further, we can create $1 - 2\pi$ level credible intervals via the π and $1 - \pi$ quantiles of the posterior, $(\hat{S}_{\pi}(t|\mathbf{x}), \hat{S}_{1-\pi}(t|\mathbf{x}))$, such that $\hat{S}_p(t|\mathbf{x}) = S_{m_p}(t|\mathbf{x})$ where m_p is the posterior draw corresponding to the $p = \pi$, or $p = 1 - \pi$, quantile respectively.

6 Restricted mean survival time (RMST)

The restricted mean survival time (RMST) is an alternative measure that is fairly interpretable (Royston and Parmar, 2013; Pak et al., 2017; Kloecker et al., 2020). The mean survival time requires an infinite integral: $\int_0^\infty S(s|\boldsymbol{x})\mathrm{d}s$. However, this is impractical, i.e., an observation period can't be lengthened until every patient passes away. Therefore, RMST limits the observation period up until time τ : RMST $(\tau) = \int_0^\tau S(s|\boldsymbol{x})\mathrm{d}s$.

To calculate RMST from an NFT BART model, consider a log-Normal time-to-event, e^z , where $z \sim N(\mu, \sigma^2)$. This leads to the following intermediate result (a completing the square

calculation reminiscent of the Moment Generating Function identity).

$$E\left[e^{z}|z < \log(\tau)\right] = (\sigma\sqrt{2\pi})^{-1} \int_{-\infty}^{\log(\tau)} e^{z - \frac{(z-\mu)^{2}}{2\sigma^{2}}} dz$$

$$= e^{\mu + \sigma^{2}/2} (\sigma\sqrt{2\pi})^{-1} \int_{-\infty}^{\log(\tau)} e^{-\frac{(z-(\mu+\sigma^{2}))^{2}}{2\sigma^{2}}} dz$$

$$= e^{\mu + \sigma^{2}/2} \Phi\left(\frac{\log(\tau) - (\mu + \sigma^{2})}{\sigma}\right)$$

For NFT BART, we have a DP mixture of log-Normals: $\log(t) = z^*$ where $z^* \sim \sum_j \omega_j [z_j]$ and $[z_j]$ is N(μ_j , σ_j^2). Now, we need the probability, p, that z^* falls within the observation period.

$$p = P[z^* < \log(\tau)] = \sum_j \omega_j \int_{-\infty}^{\log(\tau)} [z_j] dz_j = \sum_j \omega_j p_j \text{ where } p_j = \Phi\left[\frac{\log(\tau) - \mu_j}{\sigma_j}\right]$$

We derive this next key result by recognizing that the RMST is simply the expectation of the following random variable: $s = \min(t, \tau)$.

$$RMST(\tau) = E[s]$$

$$= \int_{-\infty}^{\log(\tau)} e^{z^*} [z^*] dz^* + \tau \int_{\log(\tau)}^{\infty} [z^*] dz^*$$

$$= E[e^{z^*}|z^*| < \log(\tau)] + q\tau \text{ where } q = 1 - p$$

This result can be decomposed into its atoms step-by-step.

$$E\left[e^{z^*}|z^* < \log(\tau)\right] = \sum_{j} \omega_j E\left[e^{z_j}|z_j < \log(\tau)\right]$$

$$E\left[e^{z_j}|z_j < \log(\tau)\right] = \pi_j e^{\mu_j + \sigma_j^2/2} \text{ where } \pi_j = \Phi\left(\frac{\log(\tau) - (\mu_j + \sigma_j^2)}{\sigma_j}\right)$$

$$E\left[e^{z^*}|z^* < \log(\tau)\right] = \sum_{j} \omega_j \pi_j e^{\mu_j + \sigma_j^2/2}$$

So, finally, arriving at the result of interest: RMST(τ) = E[s] = $q\tau + \sum_{j} \omega_{j} \pi_{j} e^{\mu_{j} + \sigma_{j}^{2}/2}$.

7 Marginal effects

Friedman's partial dependence function (FPD) is a common choice for estimating marginal effects via nonparametric regression and/or machine learning applications (Friedman, 2001). We divide the covariates into a subset of interest, A, and their complement, B, where all

covariates are $A \cup B$. The covariates of interest are fixed at settings of interest: a single setting denoted x_A . The complement take on the observed values found in the training data set, denoted x_{iB} for subject i, with the corresponding setting for all covariates denoted as (x_A, x_{iB}) .

Notationally, let the unknown parameters be $\boldsymbol{\theta} = (\mu, \sigma^2, \boldsymbol{\mu}, \boldsymbol{\tau}, \alpha)$ where $\boldsymbol{\theta}_m$ is for the mth posterior draw; and, similarly, let $\boldsymbol{\theta}_i = (\mu, \sigma^2, \mu_i, \tau_i, \alpha)$ with corresponding $\boldsymbol{\theta}_{im}$. Formally, we have an interest in the marginal expectation $\widehat{y}_A = \mathrm{E}\left[y|\boldsymbol{x}_A\right]$. So, consider the draws of $\widehat{y}_{Am} = \int \mathrm{E}\left[y|\boldsymbol{x}_A, \boldsymbol{x}_B, \boldsymbol{\theta}_m\right] [\boldsymbol{x}_B|\boldsymbol{x}_A] \,\mathrm{d}\boldsymbol{x}_B$. Full evaluation of this conditional expectation can be challenging in practice due to the need for characterizing the conditional distribution $[\boldsymbol{x}_B|\boldsymbol{x}_A]$. The FPD function approximates this quantity under an assumption of independence by averaging over the observed marginal covariate distribution of \boldsymbol{x}_B to get $\widehat{y}_{Am} \approx N^{-1} \sum_i \mathrm{E}\left[y|\boldsymbol{x}_A, \boldsymbol{x}_{iB}, \boldsymbol{\theta}_m\right]$ for the mth posterior draw. We conceptually extend the FPD technique to an NFT BART marginal expectation by the following simple adaptation: $\widehat{y}_{Am} \approx N^{-1} \sum_i \mathrm{E}\left[y_i|\boldsymbol{x}_A, \boldsymbol{x}_{iB}, \boldsymbol{\theta}_{im}\right] = N^{-1} \sum_i \left(\mu_{im} + \mu_m(\boldsymbol{x}_A, \boldsymbol{x}_{iB})\right)$ leading to the result $\widehat{y}_A = M^{-1} \sum_m \widehat{y}_{Am}$. Similarly, FPD can be employed for more complex functions of the posterior such as the survival. We arrive at the survival marginal effect for setting \boldsymbol{x}_A for NFT BART, in two steps, as follows (conditioning on $\boldsymbol{\theta}$ suppressed for notational convenience).

$$\begin{cases}
F_{Am}(t|\boldsymbol{x}_A) &= N^{-1} \sum_{i} \Phi\left(\frac{\log t - \mu_{im} - \mu_{m}(\boldsymbol{x}_A, \boldsymbol{x}_{iB})}{\sigma_{im}\sigma_{m}(\boldsymbol{x}_A, \boldsymbol{x}_{iB})}\right) \\
\widehat{S}_A(t|\boldsymbol{x}_A) &= 1 - M^{-1} \sum_{m} F_{Am}(t|\boldsymbol{x}_A)
\end{cases}$$

And, finally, credible intervals for the marginal effects are provided by the posterior quantiles as shown above.

8 Software Implementation


The software necessary to implement the methodology explored in this article is not trivial to implement. We relied upon the **nftbart** R package that is publicly available online hosted on the Comprehensive R Archive Network (CRAN) (Sparapani et al., 2023). The **nftbart** package relied on several key computational methods some of which were explored in this article. The next section demonstrates an example discussing missing data imputation and the marginal effects methodology employed here. Furthermore, the Gibbs conditionals necessary for NFT BART are shown in the previous section. Other computational methods employed, besides BART (Chipman et al., 2010) and HBART (Pratola et al., 2020), include efficient BART/HBART posterior sampling (Pratola, 2016), efficient DPM sampling (Neal, 2000), constrained DPM (Yang et al., 2010), DPM LIO (Shi et al., 2019) and data augmentation for left-/right-censoring (Henderson et al., 2020).

With the **nftbart** R package, we present a real data example of an advanced lung cancer study (Loprinzi et al., 1994). Two-hundred and twenty-eight subjects with lung cancer were followed by the North Central Cancer Treatment Group for a median of roughly one year. Several covariates of interest were collected including age, sex, daily activity performance scores, diet and weight-loss information. All of these variables were largely non-missing with the exception of the calories consumed at meals for which missingness was 20.6%.

For this limited amount of missing data, we utilized record-level cold-decking imputation that is biased towards the null. The name reflects its similarity to hot-decking (de Waal et al., 2011) except that no attempt is made to locate a nearby/hot neighbor based on the outcome nor any other covariate criteria, i.e., cold-decking is a simple random sampling of a non-missing subject's record to replace the missing values with. For subject's with multiple missing values, the joint relationships between covariates are maintained by replacing all of the missing values from the non-missing subject randomly chosen. This simple missing data imputation method is sufficient for data sets with relatively few missing values; for more prevalent missingness we recommend the sequential BART algorithm (Xu et al., 2016).

For this example, sex was determined to be the most important covariate by Thompson Sampling Variable Selection (TSVS) (Liu and Ročková, 2023; Sparapani et al., 2023) with 138 male and 90 female participants. To demonstrate a common computation with **nftbart**, we will compare the survival experience of males vs. females by their marginal effects with Friedman's partial dependence function (Friedman, 2001) (as described in 7). As we can see in Supplement Figure 1, females generally have longer survival; however, for advanced lung cancer the prognosis is dire in the era of the collected data since the survival probability declines precipitously for both sexes. This demonstration is included with the **nftbart** package. You can install the **nftbart** R package and run this example as follows (use a nearby CRAN mirror for best results; see http://cran.r-project.org/mirrors.html).

```
> options(repos=c(CRAN="http://cran.r-project.org"))
> install.packages("nftbart", dependencies=TRUE)
> ## system.file() returns the location where lung.R is installed
> system.file("demo/lung.R", package="nftbart")
> source(system.file("demo/lung.R", package="nftbart"))
> ## demo("lung", package="nftbart") ## via the demo() facility
```



Supplement Figure 1: Advanced lung cancer study example: males vs. females. Two-hundred and twenty-eight subjects with lung cancer were followed by the North Central Cancer Treatment Group for a median of roughly one year: 138 male and 90 female participants. For this data set, statistical inference was performed with NFT BART for the collected covariates including age, sex, daily activity performance scores, diet and weight-loss information. The solid lines summarize the survival marginal effect for males (blue) and females (red) where the dashed lines are 95% credible intervals.

9 Additional details

9.1 Model variables

First, we provide tabulations for the additional covariates in the model, 41 in total: Supplementary Tables 2, 3, 4, and 5. Furthermore, we have a comparison of the actual matched donor from the search archive along with two potential matches: the youngest female and the youngest male: Supplementary Tables 6.

This is a good point to elaborate on when cold-decking missing imputation was employed (as described in the previous section). For a global variable with missigness such as "Recipient CMV+", cold-decking was performed. And the same imputation per recipient was used for both OS and EFS calculations. However, for a disease-specific covariate like "ALL immunotype", this wouldn't work well. In this case, cold-decking would very likely just draw another missing value since only 13% of the recipients were transplanted due to ALL: we could keep drawing, but for a large data set (as we have here) that is time-consuming. So, for disease-specific variables such as these, we employed a missing value category rather than imputation.

Supplement Table 2: Recipient demographic characteristics. Training and validation sets are mutually exclusive while search archive is a subset of validation.

	Training set		Validation set		Search archive		Overall total	
Recipient CMV+	9968		1787		691		11755	
Yes	6021	60.4%	1078	60.3%	420	60.8%	7099	60.4%
Missing	48		15		8		63	
Ventilation history	10012		1801		699		11813	
Yes	367	3.7%	67	3.7%	23	3.3%	434	3.7%
Missing	4		1		0		5	
Invasive fungal history	10009		1801		699		11810	
Yes	421	4.2%	83	4.6%	40	5.7%	504	4.3%
Missing	7		1		0		8	

CMV: cytomegalovirus

Supplement Table 3: Disease and transplant characteristics: part 1. Training and validation sets are mutually exclusive while search archive is a subset of validation.

Disease	are mutually exclusive wille search		ng set	Validation set		Search archive		Overall total	
AML 3956 39.5% 746 41.4% 290 41.5% 4702 39.8% CLL 139 1.4% 26 1.4% 10 1.4% 165 1.4% CML 269 2.7% 47 2.6% 22 3.1% 316 2.7% MDS 1988 19.8% 362 20.1% 139 19.9% 2350 19.9% MM 128 1.3% 26 1.4% 10 1.4% 154 1.3% NHL 617 6.2% 94 5.2% 37 5.3% 711 6.0% Other 1629 16.3% 250 13.9% 89 12.7% 1879 15.9% From diagnosis to transplant 9995 1796 695 111791 6.0% 695 111791 6.0% 695 111791 6.0% 695 111791 15.9% 752 42.0% 285 41.0% 505 53.0% 696 15.2%	Disease			1802		699		11818	
CLL 139 1.4% 26 1.4% 10 1.4% 165 1.4% CML 269 2.7% 47 2.6% 22 3.1% 316 2.7% MDS 1988 19.8% 362 20.1% 139 19.9% 2350 19.9% MM 128 1.3% 26 1.4% 10 1.4% 154 1.3% NHL 617 6.2% 94 5.2% 37 5.3% 711 6.0% Other 1629 16.3% 250 13.9% 89 12.7% 1879 15.9% From diagnosis to transplant 1629 16.3% 250 13.9% 89 12.7% 1879 15.9% From diagnosis to transplant 4311 43.1% 754 42.0% 285 41.0% 5065 43.0% 6-6.12 400 43 13.0 43.1% 43.1% 42.0% 285 41.0% 5065 29.8% <t< td=""><td>ALL</td><td>1290</td><td>12.9%</td><td>251</td><td>13.9%</td><td>102</td><td>14.6%</td><td>1541</td><td>13.0%</td></t<>	ALL	1290	12.9%	251	13.9%	102	14.6%	1541	13.0%
CML 269 2.7% 47 2.6% 22 3.1% 316 2.7% MDS 1988 19.8% 362 20.1% 139 19.9% 2350 19.9% MM 128 1.3% 26 1.4% 10 1.4% 154 1.3% NHL 617 6.2% 94 5.2% 37 5.3% 711 6.0% Other 1629 16.3% 250 13.9% 89 12.7% 1879 15.9% From diagnosis to transplant 9995 1796 695 11791 10.9% 6:12 months 2511 25.1% 475 26.4% 186 26.8% 2986 25.3% >12:18 months 785 7.9% 151 8.4% 59 8.5% 936 7.9% >12:18 months 457 4.6% 89 5.0% 40 5.8% 546 4.6% >24 months 1931 19.3% 327 18.2% <	AML	3956	39.5%	746	41.4%	290	41.5%	4702	39.8%
MDS 1988 19.8% 362 20.1% 139 19.9% 2350 19.9% MM 128 1.3% 26 1.4% 10 1.4% 154 1.3% NHL 617 6.2% 94 5.2% 37 5.3% 711 60% Other 1639 16.3% 250 13.9% 89 12.7% 1879 15.9% From diagnosis to transplant 695 1796 695 11791 10.6 10.6 11791 10.6 10.6 10.6 10.6 10.6 10.6 10.0 50.65 43.0% 50.65 43.0% 50.65 43.0% 50.65 43.0% 50.65 43.0% 50.65 43.0% 50.65 43.0% 50.65 43.0% 50.65 43.0% 50.65 43.0% 50.7% 51.1 8.4% 59 8.5% 936 25.3% 50.7% 51.2 18.2% 69.9 8.5% 936 40.2 18.2% 69.9 1	CLL	139	1.4%	26	1.4%	10	1.4%	165	1.4%
MMM 128 1.3% 26 1.4% 10 1.4% 154 1.3% NHL 617 6.2% 94 5.2% 37 5.3% 711 6.0% Other 1629 16.3% 250 13.9% 89 12.7% 1879 15.9% From diagnosis to transplant 9995 1796 695 11791 0.6 months 4311 43.1% 754 42.0% 285 41.0% 5065 43.0% >6:12 months 2511 25.1% 475 26.4% 186 26.8% 2986 25.3% >12:18 months 785 7.9% 151 8.4% 59 8.5% 936 7.9% >18:24 months 457 4.6% 89 5.0% 40 5.8% 546 4.6% >24 months 1931 19.3% 327 18.2% 125 18.0% 2258 19.2% Missing 21 6 4 22 127	CML	269	2.7%	47	2.6%	22	3.1%	316	2.7%
NHL Other 617 logg 6.2% logg 94 logg 5.2% logg 37 logg 5.3% logg 711 logg 6.0% logg From diagnosis to transplant 0.6 months 4311 logg 43.1% logg 754 logg 42.0% logg 285 logg 41.0% logg 5065 logg 43.0% logg 7.9% logg 5065 logg 43.0% logg 7.9% logg 5066 logg 45.5% logg 5066 logg 7.9% logg	MDS	1988	19.8%	362	20.1%	139	19.9%	2350	19.9%
Other 1629 16.3% 250 13.9% 89 12.7% 1879 15.9% From diagnosis to transplant 9995 1796 695 11791 0.6 months 4311 43.1% 754 42.0% 285 41.0% 5065 43.0% >6:12 months 2511 25.1% 475 26.4% 186 26.8% 2986 25.3% >12:18 months 785 7.9% 151 8.4% 59 8.5% 936 7.9% >18:24 months 457 4.6% 89 5.0% 40 5.8% 546 4.6% >24 months 1931 19.3% 327 18.2% 125 18.0% 2258 19.2% Missing 21 6 4 27 27 27 20 11818 27 25 12.0% 258 19.2% 48.% 48 4.8% 44 6.3% 567 4.8% 48 4.8% 48 4.8% 48 <td>MM</td> <td>128</td> <td>1.3%</td> <td>26</td> <td>1.4%</td> <td>10</td> <td>1.4%</td> <td>154</td> <td>1.3%</td>	MM	128	1.3%	26	1.4%	10	1.4%	154	1.3%
From diagnosis to transplant 9995 1796 695 11791 0:6 months 4311 43.1% 754 42.0% 285 41.0% 5065 43.0% >6:12 months 2511 25.1% 475 26.4% 186 26.8% 2986 25.3% >12:18 months 785 7.9% 151 8.4% 59 8.5% 936 7.9% >18:24 months 457 4.6% 89 5.0% 40 5.8% 546 4.6% >24 months 1931 19.3% 327 18.2% 125 18.0% 2258 19.2% Missing 21 6 4 27 Prior autologous 10016 1802 699 11818 Yes 480 4.8% 87 4.8% 44 6.3% 567 4.8% ATG/Campath 10016 1802 699 11818 18 18 4.2% 42 2 423 3.8.% 696	NHL	617	6.2%	94	5.2%	37	5.3%	711	6.0%
0:6 months 4311 43.1% 754 42.0% 285 41.0% 5065 43.0% >6:12 months 2511 25.1% 475 26.4% 186 26.8% 2986 25.3% >12:18 months 785 7.9% 151 8.4% 59 8.5% 936 7.9% >18:24 months 457 4.6% 89 5.0% 40 5.8% 546 4.6% >24 months 1931 19.3% 327 18.2% 125 18.0% 2258 19.2% Missing 21 6 4 27 27 27 480 4.8% 87 4.8% 44 6.3% 567 4.8% ATG/Campath 10016 1802 699 11818 188 48 4.8% 44 6.3% 567 4.8% ALL/AML cycles to CR1 5246 997 392 6243 1 6.6% 2 69.9% 4231 68.6% 2 2.26%	Other	1629	16.3%	250	13.9%	89	12.7%	1879	15.9%
>6:12 months 2511 25.1% 475 26.4% 186 26.8% 2986 25.3% >12:18 months 785 7.9% 151 8.4% 59 8.5% 936 7.9% >18:24 months 457 4.6% 89 5.0% 40 5.8% 546 4.6% >24 months 1931 19.3% 327 18.2% 125 18.0% 2258 19.2% Missing 21 6 4 27 27 Prior autologous 10016 1802 699 11818 188 Yes 480 4.8% 87 4.8% 44 6.3% 567 4.8% ATG/Campath 10016 1802 699 11818 188 48% 44 6.3% 567 4.8% ALL/AML cycles to CR1 5246 997 392 6243 1 6243 1 1 1 1 1 1 1 1 1 1	From diagnosis to transplant	9995		1796		695		11791	
>12:18 months 785 7.9% 151 8.4% 59 8.5% 936 7.9% >18:24 months 457 4.6% 89 5.0% 40 5.8% 546 4.6% >24 months 1931 19.3% 327 18.2% 125 18.0% 2258 19.2% Missing 21 6 4 27 7 18.18 Yes 480 4.8% 87 4.8% 44 6.3% 567 4.8% ATG/Campath 10016 1802 699 11818 7 7 7 7 4.8% 44 6.3% 567 4.8% 4 6.3% 567 4.8% 4 6.3% 567 4.8% 4 6.3% 567 4.8% 4 6.3% 567 4.8% 4 6.3% 567 4.8% 4 6.3% 4551 38.5% 6 38.6% 296 42.3% 4551 38.5% 6 21.3% 42.3% <td< td=""><td>0:6 months</td><td>4311</td><td>43.1%</td><td>754</td><td>42.0%</td><td>285</td><td>41.0%</td><td>5065</td><td>43.0%</td></td<>	0:6 months	4311	43.1%	754	42.0%	285	41.0%	5065	43.0%
>18:24 months 457 4.6% 89 5.0% 40 5.8% 546 4.6% >24 months 1931 19.3% 327 18.2% 125 18.0% 2258 19.2% Missing 21 6 4 27 Prior autologous 10016 1802 699 11818 4.8% ATG/Campath 10016 1802 699 11818 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.8% 4.4 6.3% 567 4.8% ATG/Campath 10016 1802 699 11818 7.8% 4.8% 4.4 6.3% 4551 38.5% 6.6% 4.23 42.3% 4551 38.5% 6.6 6.99 42.81 68.6% 6.6% 6.6% 2.21 6.99 42.81 68.6% 6.6%	>6:12 months	2511	25.1%	475	26.4%	186	26.8%	2986	25.3%
>24 months 1931 19.3% 327 18.2% 125 18.0% 2258 19.2% Missing 21 6 4 27 Prior autologous 10016 1802 699 11818 Yes 480 4.8% 87 4.8% 44 6.3% 567 4.8% ATG/Campath 10016 1802 699 11818 4.8% Yes 3855 38.5% 696 38.6% 296 42.3% 4551 38.5% ALL/AML cycles to CR1 5246 997 392 6243 66.6% 2 1044 19.9% 225 22.6% 86 21.9% 1269 20.3% 3+ 595 11.3% 98 9.8% 32 8.2% 693 11.1% ALL Ph chromosome 1290 251 102 1541 1589 11.3% Feell 181 14.2% 37 14.8% 16 15.8% 218	>12:18 months	785	7.9%	151	8.4%	59	8.5%	936	7.9%
Missing 21 6 4 27 Prior autologous 10016 1802 699 11818 Yes 480 4.8% 87 4.8% 44 6.3% 567 4.8% ATG/Campath 10016 1802 699 11818 188 188 488 44 6.3% 4551 38.5% 696 38.6% 296 42.3% 4551 38.5% 696 38.6% 296 42.3% 4551 38.5% 68 21.0% 4251 38.5% 68 21.0% 4251 38.5% 68 21.0% 4281 68.6% 68 21.0% 4281 68.6% 68 21.9% 4281 68.6% 22 10.4 19.9% 225 22.6% 86 21.9% 1269 20.3% 34.3% 503 31.1% 32 8.2% 693 11.1% 11.1% 1.2 11.4% 44.2% 332.8% 80 31.9% 35 34.3% 503 32.6	>18:24 months	457	4.6%	89	5.0%	40	5.8%	546	4.6%
Prior autologous 10016 1802 699 11818 Yes 480 4.8% 87 4.8% 44 6.3% 567 4.8% ATG/Campath 10016 1802 699 11818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818 1818	>24 months	1931	19.3%	327	18.2%	125	18.0%	2258	19.2%
Yes 480 4.8% 87 4.8% 44 6.3% 567 4.8% ATG/Campath 10016 1802 699 11818 11818 Yes 3855 38.5% 696 38.6% 296 42.3% 4551 38.5% ALL/AML cycles to CR1 5246 997 392 6243 1 3607 68.8% 674 67.6% 274 69.9% 4281 68.6% 2 1044 19.9% 225 22.6% 86 21.9% 1269 20.3% 3+ 595 11.3% 98 9.8% 32 8.2% 693 11.1% Yes 423 32.8% 80 31.9% 35 34.3% 503 32.6% ALL immunotype 1279 250 101 1529 T-cell 181 14.2% 37 14.8% 16 15.8% 218 14.3% B-cell 1098 85.8% 213 85.2%	Missing	21		6		4		27	
ATG/Campath 10016 1802 699 11818 Yes 3855 38.5% 696 38.6% 296 42.3% 4551 38.5% ALL/AML cycles to CR1 5246 997 392 6243 1 3607 68.8% 674 67.6% 274 69.9% 4281 68.6% 2 1044 19.9% 225 22.6% 86 21.9% 1269 20.3% 3+ 595 11.3% 98 9.8% 32 8.2% 693 11.1% ALL Ph chromosome 1290 251 102 1541 1541 1541 1541 1541 1541 1541 1549 1541 1549 1541 1549 1541 1549 1541 1549 1541 1541 1544 1544 1544 1544 1544 1544 1544 1544 1544 1544 1544 1544 1544 1544 1544 1544 1544 1544	Prior autologous	10016		1802		699		11818	
Yes 3855 38.5% 696 38.6% 296 42.3% 4551 38.5% ALL/AML cycles to CR1 5246 997 392 6243 1 3607 68.8% 674 67.6% 274 69.9% 4281 68.6% 2 1044 19.9% 225 22.6% 86 21.9% 1269 20.3% 3+ 595 11.3% 98 9.8% 32 8.2% 693 11.1% ALL Ph chromosome 1290 251 102 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541 1541	Yes	480	4.8%	87	4.8%	44	6.3%	567	4.8%
ALL/AML cycles to CR1 5246 997 392 6243 1 3607 68.8% 674 67.6% 274 69.9% 4281 68.6% 2 1044 19.9% 225 22.6% 86 21.9% 1269 20.3% 3+ 595 11.3% 98 9.8% 32 8.2% 693 11.1% ALL Ph chromosome 1290 251 102 1541 Yes 423 32.8% 80 31.9% 35 34.3% 503 32.6% ALL immunotype 1279 250 101 1529 T-cell 181 14.2% 37 14.8% 16 15.8% 218 14.3% B-cell 1098 85.8% 213 85.2% 85 84.2% 1311 85.7% Missing 11 1 1 1 1 1 1 ALL cytogene 1290 251 102 1541 Normal 238 18.4% 59 23.5% 26 25.5% 297	ATG/Campath	10016		1802		699		11818	
1 3607 68.8% 674 67.6% 274 69.9% 4281 68.6% 2 1044 19.9% 225 22.6% 86 21.9% 1269 20.3% 3+ 595 11.3% 98 9.8% 32 8.2% 693 11.1% ALL Ph chromosome 1290 251 102 1541 Yes 423 32.8% 80 31.9% 35 34.3% 503 32.6% ALL immunotype 1279 250 101 1529 T-cell 181 14.2% 37 14.8% 16 15.8% 218 14.3% B-cell 1098 85.8% 213 85.2% 85 84.2% 1311 85.7% Missing 11 1 1 1 12 ALL cytogene 1290 251 102 1541 Normal 238 18.4% 59 23.5% 26 25.5% 297 19.3% Poor 787 61.0% 136 54.2% 47 46	Yes	3855	38.5%	696	38.6%	296	42.3%	4551	38.5%
2 1044 19.9% 225 22.6% 86 21.9% 1269 20.3% 3+ 595 11.3% 98 9.8% 32 8.2% 693 11.1% ALL Ph chromosome 1290 251 102 1541 Yes 423 32.8% 80 31.9% 35 34.3% 503 32.6% ALL immunotype 1279 250 101 1529 T-cell 181 14.2% 37 14.8% 16 15.8% 218 14.3% B-cell 1098 85.8% 213 85.2% 85 84.2% 1311 85.7% Missing 11 1 1 1 12 ALL cytogene 1290 251 102 1541 Normal 238 18.4% 59 23.5% 26 25.5% 297 19.3% Poor 787 61.0% 136 54.2% 47 46.1% 923 59.9% Other 265 20.5% 56 22.3% 29 28	ALL/AML cycles to CR1	5246		997		392		6243	
3+ 595 11.3% 98 9.8% 32 8.2% 693 11.1% ALL Ph chromosome 1290 251 102 1541 Yes 423 32.8% 80 31.9% 35 34.3% 503 32.6% ALL immunotype 1279 250 101 1529 T-cell 181 14.2% 37 14.8% 16 15.8% 218 14.3% B-cell 1098 85.8% 213 85.2% 85 84.2% 1311 85.7% Missing 11 1 1 1 12 ALL cytogene 1290 251 102 1541 Normal 238 18.4% 59 23.5% 26 25.5% 297 19.3% Poor 787 61.0% 136 54.2% 47 46.1% 923 59.9% Other 265 20.5% 56 22.3% 29 28.4% 321 2		3607	68.8%	674	67.6%	274	69.9%	4281	68.6%
ALL Ph chromosome 1290 251 102 1541 Yes 423 32.8% 80 31.9% 35 34.3% 503 32.6% ALL immunotype 1279 250 101 1529 T-cell 181 14.2% 37 14.8% 16 15.8% 218 14.3% B-cell 1098 85.8% 213 85.2% 85 84.2% 1311 85.7% Missing 11 1 1 12 1541 Normal 238 18.4% 59 23.5% 26 25.5% 297 19.3% Poor 787 61.0% 136 54.2% 47 46.1% 923 59.9% Other 265 20.5% 56 22.3% 29 28.4% 321 20.8% ALL BCR/ABL marker 1290 251 102 1541	2	1044	19.9%	225	22.6%	86	21.9%	1269	20.3%
Yes 423 32.8% 80 31.9% 35 34.3% 503 32.6% ALL immunotype 1279 250 101 1529 T-cell 181 14.2% 37 14.8% 16 15.8% 218 14.3% B-cell 1098 85.8% 213 85.2% 85 84.2% 1311 85.7% Missing 11 1 1 12 12 ALL cytogene 1290 251 102 1541 Normal 238 18.4% 59 23.5% 26 25.5% 297 19.3% Poor 787 61.0% 136 54.2% 47 46.1% 923 59.9% Other 265 20.5% 56 22.3% 29 28.4% 321 20.8% ALL BCR/ABL marker 1290 251 102 1541	3+	595	11.3%	98	9.8%	32	8.2%	693	11.1%
ALL immunotype 1279 250 101 1529 T-cell 181 14.2% 37 14.8% 16 15.8% 218 14.3% B-cell 1098 85.8% 213 85.2% 85 84.2% 1311 85.7% Missing 11 1 1 1 12 ALL cytogene 1290 251 102 1541 Normal 238 18.4% 59 23.5% 26 25.5% 297 19.3% Poor 787 61.0% 136 54.2% 47 46.1% 923 59.9% Other 265 20.5% 56 22.3% 29 28.4% 321 20.8% ALL BCR/ABL marker 1290 251 102 1541	ALL Ph chromosome	1290		251		102		1541	
T-cell 181 14.2% 37 14.8% 16 15.8% 218 14.3% B-cell 1098 85.8% 213 85.2% 85 84.2% 1311 85.7% Missing 11 1 1 1 12 ALL cytogene 1290 251 102 1541 Normal 238 18.4% 59 23.5% 26 25.5% 297 19.3% Poor 787 61.0% 136 54.2% 47 46.1% 923 59.9% Other 265 20.5% 56 22.3% 29 28.4% 321 20.8% ALL BCR/ABL marker 1290 251 102 1541	Yes	423	32.8%	80	31.9%	35	34.3%	503	32.6%
B-cell 1098 85.8% 213 85.2% 85 84.2% 1311 85.7% Missing 11 1 1 1 12 ALL cytogene 1290 251 102 1541 Normal 238 18.4% 59 23.5% 26 25.5% 297 19.3% Poor 787 61.0% 136 54.2% 47 46.1% 923 59.9% Other 265 20.5% 56 22.3% 29 28.4% 321 20.8% ALL BCR/ABL marker 1290 251 102 1541	ALL immunotype	1279		250		101		1529	
Missing 11 1 1 12 ALL cytogene 1290 251 102 1541 Normal 238 18.4% 59 23.5% 26 25.5% 297 19.3% Poor 787 61.0% 136 54.2% 47 46.1% 923 59.9% Other 265 20.5% 56 22.3% 29 28.4% 321 20.8% ALL BCR/ABL marker 1290 251 102 1541	T-cell	181	14.2%	37	14.8%	16	15.8%	218	14.3%
ALL cytogene 1290 251 102 1541 Normal 238 18.4% 59 23.5% 26 25.5% 297 19.3% Poor 787 61.0% 136 54.2% 47 46.1% 923 59.9% Other 265 20.5% 56 22.3% 29 28.4% 321 20.8% ALL BCR/ABL marker 1290 251 102 1541	B-cell	1098	85.8%	213	85.2%	85	84.2%	1311	85.7%
Normal 238 18.4% 59 23.5% 26 25.5% 297 19.3% Poor 787 61.0% 136 54.2% 47 46.1% 923 59.9% Other 265 20.5% 56 22.3% 29 28.4% 321 20.8% ALL BCR/ABL marker 1290 251 102 1541	Missing	11		1		1		12	
Poor Other 787 61.0% of 136 54.2% of 20.5% of 22.3% of 29 47 46.1% of 20.4% of 20.8% of 22.3% of 29 923 59.9% of 20.8% of 20.8% of 22.3% of 29 ALL BCR/ABL marker 1290 251 102 1541	ALL cytogene	1290		251		102		1541	
Other 265 20.5% 56 22.3% 29 28.4% 321 20.8% ALL BCR/ABL marker 1290 251 102 1541	Normal	238	18.4%	59	23.5%	26	25.5%	297	19.3%
ALL BCR/ABL marker 1290 251 102 1541	Poor	787	61.0%	136	54.2%	47	46.1%	923	59.9%
,	Other	265	20.5%	56	22.3%	29	28.4%	321	20.8%
Yes 207 16.0% 44 17.5% 21 20.6% 251 16.3%	ALL BCR/ABL marker	1290		251		102		1541	
	Yes	207	16.0%	44	17.5%	21	20.6%	251	16.3%

ABL: Abelson interactor 1 gene, ALL: acute lymphoblastic leukemia,

AML: acute myelogenous leukemia, ATG: anti-thymocyte globulin,

BCR: breakpoint cluster region gene, CLL: chronic lymphocytic leukemia,

CML: chronic myelogenous leukemia, CR1: first complete remission,

MDS: myelodysplastic syndrome, MM: multiple myeloma, NHL: non-Hodgkin's lymphoma.

Supplement Table 4: Disease and transplant characteristics: part 2. Training and validation sets are mutually exclusive while search archive is a subset of validation.

	Training set		Validation set		Search archive		Overall total	
AML cytogene	3956		746		290		4702	
Normal	259	6.5%	60	8.0%	31	10.7%	319	6.8%
Favorable	789	19.9%	133	17.8%	47	16.2%	922	19.6%
Intermediate	1249	31.6%	254	34.0%	102	35.2%	1503	32.0%
Poor	1641	41.5%	293	39.3%	107	36.9%	1934	41.1%
APL	18	0.5%	6	0.8%	3	1.0%	24	0.5%
AML progression from MDS	3956		746		290		4702	
Yes	550	13.9%	101	13.5%	43	14.8%	651	13.8%
AML therapy-related	3956		746		290		4702	
Yes	306	7.7%	66	8.8%	20	6.9%	372	7.9%
MDS predisposed	1988		362		139		2350	
Yes	99	5.0%	11	3.0%	6	4.3%	110	4.7%
MDS therapy-related	1988		362		139		2350	
Yes	385	19.4%	57	15.7%	23	16.5%	442	18.8%

AML: acute myelogenous leukemia, APL: acute promyelocytic leukemia,

MDS: myelodysplastic syndrome.

Supplement Table 5: Disease and transplant characteristics: part 3. Training and validation sets are mutually exclusive while search archive is a subset of validation.

utuany exclusive wille s		ning set		Validation set		rch archive	Overall total	
CLL status	139		26		10		165	
Complete remission	66	47.5%	12	46.2%	4	40.0%	78	47.3%
Partial remission	45	32.4%	11	42.3%	5	50.0%	56	33.9%
Stable	28	20.1%	3	11.5%	1	10.0%	31	18.8%
CLL 17p	139		26		10		165	
Yes	50	36.0%	11	42.3%	4	40.0%	61	37.0%
CML status	269		47		22		316	
Hematologic CR	99	36.8%	17	36.2%	7	31.8%	116	36.7%
Chronic phase	124	46.1%	27	57.4%	13	59.1%	151	47.8%
Accelerated phase	46	17.1%	3	6.4%	2	9.1%	49	15.5%
MM ISS/DS stage	128		26		10		154	
1/11	45	35.2%	11	42.3%	6	60.0%	56	36.4%
III	83	64.8%	15	57.7%	4	40.0%	98	63.6%
MM cytorisk	103		20		7		123	
Normal	7	6.8%	3	15.0%	0	0.0%	10	8.1%
High	70	68.0%	8	40.0%	5	71.4%	78	63.4%
Standard	26	25.2%	9	45.0%	2	28.6%	35	28.5%
Missing	25		6		3		31	
MM status	128		26		10		154	
SCR/CR	13	10.2%	7	26.9%	3	30.0%	20	13.0%
VGPR	63	49.2%	11	42.3%	4	40.0%	74	48.1%
Partial response	34	26.6%	4	15.4%	0	0.0%	38	24.7%
Stable	8	6.3%	2	7.7%	2	20.0%	10	6.5%
Progressive/relapse	10	7.8%	2	7.7%	1	10.0%	12	7.8%
NHL subtype	617		94		37		711	
Folicular	80	13.0%	7	7.4%	2	5.4%	87	12.2%
DLBCL	188	30.5%	42	44.7%	17	45.9%	230	32.3%
MCL	95	15.4%	11	11.7%	3	8.1%	106	14.9%
Other B-cell	7	1.1%	0	0.0%	0	0.0%	7	1.0%
T-cell	247	40.0%	34	36.2%	15	40.5%	281	39.5%

CLL: chronic lymphocytic leukemia, CML: chronic myelogenous leukemia,

CR: complete response, DLBCL: diffuse large B-cell lymphoma,

ISS/DS: International Staging System/Durie-Salmon, (Hari et al., 2009)

MCL: mantle cell lymphoma, MM: multiple myeloma, NHL: non-Hodgkin's lymphoma,

SCR: stringent complete response, VGPR: very good partial response.

Supplement Table 6: Donor matching characteristics. Search archive comparison between the actual matched donor vs. potential matches: the youngest female, the youngest male and the youngest between the two.

	Actu	al donor	Youngest F		Youngest M		You	ıngest
Donor age	698		699		699		699	
17:29	479	68.6%	640	91.6%	602	86.1%	671	96.0%
30:39	146	20.9%	36	5.2%	51	7.3%	22	3.1%
40:49	52	7.4%	16	2.3%	23	3.3%	5	0.7%
50:62	21	3.0%	7	1.0%	23	3.3%	1	0.1%
Missing	1	0		0				
Donor sex	698		699		699		699	
male	524	75.1%	0	0.0%	699	100.0%	347	49.6%
Missing	1		0		0		0	

9.2 Relationships with respect to OS/EFS

Here we provide a table that cross-references each relationship with their corresponding data display(s).


Supplement Table 7: List of figures by assessed relationship.

Supplemen	Supplement Table 1. List of figures by assessed relationship.										
	09	5	EFS								
Characteristics	Marginal Effects	Waterfall Plot	Marginal Effects	Waterfall Plot							
RMST value function											
Figure 2											
Donor											
Age	Figure 3		Figure 4								
Sex/parity	Figure 5		Figure 6								
Recipient female		Figure 7		Figure 8							
Recipient male		Figure 9		Figure 10							
CMV	Figure 11	Figure 12	Figure 13	Figure 14							
DPB1	Figure 15	Figure 16	Figure 17	Figure 18							
DQB1	Figure 19	Figure 20	Figure 21	Figure 22							
Recipient											
Age	Figure 23		Figure 24								
Race	Figure 25		Figure 26								
Median income (ZCTA)	Figure 27		Figure 28								
HCT-CI	Figure 29		Figure 30								
Disease/transplant											
ALL status	Figure 31		Figure 32								
AML status	Figure 33		Figure 34								
MDS status	Figure 35		Figure 36								
Year of transplant	Figure 37		Figure 38								

ALL: acute lymphoblastic leukemia, AML: acute myelogenous leukemia, CMV: cytomegalovirus,


HCT-CI: hematopoietic cell transplant comorbidity index (Sorror et al., 2015),

MDS: myelodysplastic syndrome, ZCTA: ZIP code tabulation area.




Supplement Figure 2: Population level value function for RMST. Return to cross-reference 9.2.


9.2.1 Figures for donor characteristics




Supplement Figure 3: Marginal effect of donor age for OS: training cohort. Return to cross-reference 9.2.




Supplement Figure 4: Marginal effect of donor age for EFS: training cohort. Return to cross-reference 9.2.




Supplement Figure 5: Marginal effect of sex match for OS: training cohort. Return to cross-reference 9.2.




Supplement Figure 6: Marginal effect of sex match for EFS: training cohort. Return to cross-reference 9.2.




Supplement Figure 7: Waterfall plot of recipient females and donor sex/parity for OS: validation cohort. Return to cross-reference 9.2.




Supplement Figure 8: Waterfall plot of recipient female and donor sex/parity for EFS: validation cohort. Return to cross-reference 9.2.




Supplement Figure 9: Waterfall plot of recipient males and donor sex/parity for OS: validation cohort. Return to cross-reference 9.2.




Supplement Figure 10: Waterfall plot of recipient male and donor sex/parity for EFS: validation cohort. Return to cross-reference 9.2.




Supplement Figure 11: Marginal effect of CMV match for OS: training cohort. Return to cross-reference 9.2.




Supplement Figure 12: Waterfall plot of CMV match for OS: validation cohort. Return to cross-reference 9.2.




Supplement Figure 13: Marginal effect of CMV match for EFS: training cohort. Return to cross-reference 9.2.




Supplement Figure 14: Waterfall plot of CMV match for EFS: validation cohort. Return to cross-reference 9.2.




Supplement Figure 15: Marginal effect of DPB1 match/permissive mismatch for OS: training cohort. Return to cross-reference 9.2.




Supplement Figure 16: Waterfall plot of DPB1 match/permissive mismatch for OS: validation cohort. Return to cross-reference 9.2.




Supplement Figure 17: Marginal effect of DPB1 match/permissive mismatch for EFS: training cohort. Return to cross-reference 9.2.




Supplement Figure 18: Waterfall plot of DPB1 match/permissive mismatch for EFS: validation cohort. Return to cross-reference 9.2.




Supplement Figure 19: Marginal effect of DQB1 match for OS: training cohort. Return to cross-reference 9.2.



Supplement Figure 20: Waterfall plot of DQB1 match for OS: validation cohort. Return to cross-reference 9.2.




Supplement Figure 21: Marginal effect of DQB1 match for EFS: training cohort. Return to cross-reference 9.2.




Supplement Figure 22: Waterfall plot of DQB1 match for EFS: validation cohort. Return to cross-reference 9.2.


9.2.2 Figures for recipient characteristics




Supplement Figure 23: Marginal effect of recipient age for OS: training cohort. Return to cross-reference 9.2.




Supplement Figure 24: Marginal effect of recipient age for EFS: training cohort. Return to cross-reference 9.2.




Supplement Figure 25: Marginal effect of race for OS: training cohort. Return to cross-reference 9.2.




Supplement Figure 26: Marginal effect of race for EFS: training cohort. Return to cross-reference 9.2.




Supplement Figure 27: Marginal effect of ZIP median income for OS: training cohort. Return to cross-reference 9.2.



Supplement Figure 28: Marginal effect of ZIP median income for EFS: training cohort. Return to cross-reference 9.2.




Supplement Figure 29: Marginal effect of HCT-CI for OS: training cohort. Return to cross-reference 9.2.




Supplement Figure 30: Marginal effect of HCT-CI for EFS: training cohort. Return to cross-reference 9.2.


9.2.3 Figures for disease/transplant characteristics




Supplement Figure 31: Marginal effect of ALL status for OS: training cohort. Return to cross-reference 9.2.




Supplement Figure 32: Marginal effect of ALL status for EFS: training cohort. Return to cross-reference 9.2.




Supplement Figure 33: Marginal effect of AML status for OS: training cohort. Return to cross-reference 9.2.




Supplement Figure 34: Marginal effect of AML status for EFS: training cohort. Return to cross-reference 9.2.




Supplement Figure 35: Marginal effect of MDS status for OS: training cohort. Return to cross-reference 9.2.



Supplement Figure 36: Marginal effect of MDS status for EFS: training cohort. Return to cross-reference 9.2.



Supplement Figure 37: Marginal effect of transplant year for OS: training cohort. Return to cross-reference 9.2.



Supplement Figure 38: Marginal effect of transplant year for EFS: training cohort. Return to cross-reference 9.2.

References

Bleich J, Kapelner A, George EI and Jensen ST (2014) Variable selection for BART: an application to gene regulation. *The Annals of Applied Statistics* 8(3): 1750–1781. URL https://www.jstor.org/stable/24522283.

Chipman HA, George EI and McCulloch RE (1998) Bayesian CART model search. *Journal of the American Statistical Association* 93(443): 935–948.

Chipman HA, George EI and McCulloch RE (2010) BART: Bayesian additive regression trees. The Annals of Applied Statistics 4(1): 266–298.

de Waal T, Pannekoek J and Scholtus S (2011) Handbook of Statistical Data Editing and Imputation. Hoboken, NJ: John Wiley & Sons. DOI:10.1002/9780470904848.

- Escobar MD and West M (1995) Bayesian density estimation and inference using mixtures. Journal of the American Statistical Association 90(430): 577–588.
- Friedman JH (2001) Greedy function approximation: a gradient boosting machine. *The Annals of Statistics* 29(5): 1189–1232.
- Gelfand AE and Smith AF (1990) Sampling-based approaches to calculating marginal densities. *Journal of the American Statistical Association* 85(410): 398–409.
- Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J et al. (2009) Is the International Staging System superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. *Leukemia* 23(8): 1528–1534.
- Henderson NC, Louis TA, Rosner GL and Varadhan R (2020) Individualized treatment effects with censored data via fully nonparametric Bayesian accelerated failure time models. *Biostatistics* 21(1): 50–68.
- Kloecker DE, Davies MJ, Khunti K and Zaccardi F (2020) Uses and limitations of the restricted mean survival time: illustrative examples from cardiovascular outcomes and mortality trials in Type 2 diabetes. *Annals of internal medicine* 172(8): 541–552.
- Liu Y and Ročková V (2023) Variable selection via Thompson sampling. *Journal of the American Statistical Association* 118(541): 287–304.
- Loprinzi CL, Laurie JA, Wieand HS, Krook JE, Novotny PJ, Kugler JW et al. (1994) Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. *Journal of Clinical Oncology* 12(3): 601–607.
- Neal RM (2000) Markov chain sampling methods for Dirichlet process mixture models. *Journal of Computational and Graphical Statistics* 9(2): 249–265.
- Pak K, Uno H, Kim DH, Tian L, Kane RC, Takeuchi M, Fu H, Claggett B and Wei LJ (2017) Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio. *JAMA oncology* 3(12): 1692–1696.
- Pratola MT (2016) Efficient Metropolis–Hastings proposal mechanisms for Bayesian regression tree models. *Bayesian Analysis* 11(3): 885–911.
- Pratola MT, Chipman HA, George EI and McCulloch RE (2020) Heteroscedastic BART via multiplicative regression trees. *Journal of Computational and Graphical Statistics* 29(2): 405–417.
- Ročková V and Saha E (2019) On theory for BART. In: The 22nd International Conference on Artificial Intelligence and Statistics. PMLR, pp. 2839–2848.

- Royston P and Parmar MK (2013) Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC medical research methodology 13: 1–15.
- Shi Y, Martens M, Banerjee A and Laud P (2019) Low information omnibus (LIO) priors for Dirichlet process mixture models. *Bayesian Analysis* 14(3): 677–702.
- Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL et al. (2015) Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a Center for International Blood and Marrow Transplant Research study. *Biology of Blood and Marrow Transplantation* 21(8): 1479–1487.
- Sparapani RA, Logan BR, Maiers MJ, Laud PW and McCulloch RE (2023) Nonparametric failure time: Time-to-event machine learning with heteroskedastic Bayesian additive regression trees and low information omnibus dirichlet process mixtures. *Biometrics* 79: 3023–3037. [https://cran.r-project.org/package=nftbart].
- Xu D, Daniels MJ and Winterstein AG (2016) Sequential BART for imputation of missing covariates. *Biostatistics* 17(3): 589–602.
- Yang M, Dunson DB and Baird D (2010) Semiparametric Bayes hierarchical models with mean and variance constraints. *Computational Statistics & Data Analysis* 54(9): 2172–2186.